论文部分内容阅读
目的评价不同剂量阿托伐他汀治疗冠心病伴颈动脉斑块患者的疗效和安全性。方法选择2010年1月-2011年3月在涞源县医院治疗的冠心病伴颈动脉斑块患者81例,按照随机数字表法分为观察组和对照组,对照组40例给予阿托伐他汀10 mg/d治疗,观察组41例给予阿托伐他汀20 mg/d治疗,观察比较两组的疗效及安全性。结果治疗后两组患者的总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)均明显降低,观察组降低更为明显,组间差异有统计学意义(P<0.05);治疗后两组患者的颈总动脉内膜-中层厚度(IMT)、斑块面积明显缩小,以观察组变化更为明显,组间差异有统计学意义(P<0.05);两组均无严重不良反应发生。结论阿托伐他汀20 mg/d治疗冠心病伴颈动脉斑块患者的临床疗效更佳,能够明显改善患者的血脂水平、缩小颈动脉粥样斑块,并且安全性高,是首选的治疗方案之一。
Objective To evaluate the efficacy and safety of different doses of atorvastatin in patients with coronary artery disease and carotid artery plaque. Methods From January 2010 to March 2011, 81 patients with coronary heart disease and carotid artery plaque treated in Laiyuan County Hospital were divided into observation group and control group according to the random number table method, 40 cases in control group were given atorvastatin Statin 10 mg / d treatment, the observation group of 41 patients given atorvastatin 20 mg / d treatment, observed and compared the efficacy and safety of the two groups. Results After treatment, the total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) were significantly lower in the two groups. The reduction in the observation group was more obvious with statistically significant differences <0.05). After treatment, carotid artery intima-media thickness (IMT) and plaque area were significantly reduced in both groups, and the changes in the observation group were more obvious with statistical significance (P <0.05); No serious adverse reactions occurred in the group. Conclusions Atorvastatin 20 mg / d has better clinical efficacy in patients with coronary artery disease and carotid artery plaque, which can significantly improve the level of blood lipids and reduce carotid artery plaque, and is safe and is the first choice of treatment one.